DK1078006T3 - Diagnose og behandling af leverlidelser - Google Patents

Diagnose og behandling af leverlidelser

Info

Publication number
DK1078006T3
DK1078006T3 DK99922996T DK99922996T DK1078006T3 DK 1078006 T3 DK1078006 T3 DK 1078006T3 DK 99922996 T DK99922996 T DK 99922996T DK 99922996 T DK99922996 T DK 99922996T DK 1078006 T3 DK1078006 T3 DK 1078006T3
Authority
DK
Denmark
Prior art keywords
disorders
madcam
disorder
compositions
useful
Prior art date
Application number
DK99922996T
Other languages
English (en)
Inventor
Sherman Fong
Kenneth J Hillan
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1078006T3 publication Critical patent/DK1078006T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK99922996T 1998-05-13 1999-05-12 Diagnose og behandling af leverlidelser DK1078006T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7840598A 1998-05-13 1998-05-13
PCT/US1999/010520 WO1999058573A1 (en) 1998-05-13 1999-05-12 Diagnosis and treatment of hepatic disorders

Publications (1)

Publication Number Publication Date
DK1078006T3 true DK1078006T3 (da) 2009-06-02

Family

ID=22143829

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99922996T DK1078006T3 (da) 1998-05-13 1999-05-12 Diagnose og behandling af leverlidelser

Country Status (10)

Country Link
EP (1) EP1078006B1 (da)
JP (2) JP4817494B2 (da)
AT (1) ATE424417T1 (da)
AU (1) AU3986699A (da)
CA (1) CA2330000C (da)
DE (1) DE69940503D1 (da)
DK (1) DK1078006T3 (da)
ES (1) ES2321994T3 (da)
IL (2) IL139129A0 (da)
WO (1) WO1999058573A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60117743T2 (de) * 2001-11-05 2006-10-12 Warner-Lambert Co. Llc Screeningverfahren für Modulatoren von Integrinen
US20070202097A1 (en) * 2003-03-10 2007-08-30 Krissansen Geoffrey W Monoclonal Antibodies That Recognise Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1), Soluble Madcam-1 And Uses Thereof
CA2552523C (en) * 2004-01-09 2019-11-26 Pfizer Inc. Monoclonal antibodies to mucosal addressin cell adhesion molecule(madcam)
EP1904531B1 (en) * 2005-07-08 2010-10-06 Pfizer Limited Madcam antibodies
SI3326645T1 (sl) * 2010-10-25 2020-09-30 Biogen Ma Inc. Metode za determinacijo razlik v alfa- 4 integrin aktivnosti s korelacijo razlik v SVCAM in/ali SMADCAM nivojih
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
JP6970975B2 (ja) * 2016-07-20 2021-11-24 国立大学法人京都大学 ＩｇＧ４関連疾患の検査方法
CN111032694B (zh) 2017-07-14 2024-03-08 辉瑞大药厂 针对madcam的抗体
US20200392231A1 (en) * 2017-12-06 2020-12-17 Emory University Methods of Managing Hepatic Steatosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0808367B1 (en) * 1995-02-10 2007-07-11 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins and uses thereof
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor

Also Published As

Publication number Publication date
IL139129A0 (en) 2001-11-25
WO1999058573A1 (en) 1999-11-18
ATE424417T1 (de) 2009-03-15
CA2330000A1 (en) 1999-11-18
JP4817494B2 (ja) 2011-11-16
EP1078006A1 (en) 2001-02-28
JP2010280659A (ja) 2010-12-16
EP1078006B1 (en) 2009-03-04
ES2321994T3 (es) 2009-06-15
AU3986699A (en) 1999-11-29
CA2330000C (en) 2015-06-23
DE69940503D1 (de) 2009-04-16
IL139129A (en) 2006-09-05
JP2002514660A (ja) 2002-05-21

Similar Documents

Publication Publication Date Title
Ridker From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection
Cowper et al. Nephrogenic systemic fibrosis: an update
BR0011000A (pt) Métodos para prevenir ou tratar uma doença associada com depósitos amilóides de ab no cérebro de um paciente, para avaliar um anticorpo quanto á atividade de remoção de uma entidade biológica fisicamente associada com um antìgeno e para detectara um depósito amilóide em um paciente, composição farmacêutica, e, conjunto de diagnóstico
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
BRPI0712322A2 (pt) compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos
DK1078006T3 (da) Diagnose og behandling af leverlidelser
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
BR0008922A (pt) Compostos úteis como agentes antiinflamatórios
EP1140170A4 (en) NOVEL AGENTS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF EYE DISORDERS
EP2801366A3 (en) Improved apo E analogs and methods for their use
André et al. Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis
BRPI0206641B8 (pt) uso de um inibidor da absorção de esteróis
BRPI0606902A2 (pt) composto; método para o tratamento de uma doença ou distúrbio associado a atividade excessiva de bace em um paciente que dele necessite; método para modular a atividade de bace; composição farmacêutica
HUP0301727A2 (hu) Eljárás reumatoid artritisz kezelésére oldható mutáns CTLA4 molekula alkalmazásával
TR200002784T2 (tr) Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar
BR0308290A (pt) Tratamento e prevenção de distúrbios inflamatórios
ATE473242T1 (de) Therapeutische mittel welche einen bispezifischen anti-hla class ii invariant chain x anti-pathogen antikörper enthalten
McDonald et al. Liver complications following treatment of hematologic malignancy with anti‐CD22‐calicheamicin (Inotuzumab Ozogamicin)
BRPI0413745A (pt) horário mde dosagem para agentes anticancerìgenos erbb2
BR9814923A (pt) Método para tratamento de doença de alzheimer
NO20024646D0 (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
ATE497763T1 (de) Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
WO2008157747A8 (en) Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
Claus et al. Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam
WO2004064869A3 (en) Amyloid-binding, metal-chelating agents